Ibrutinib CAS 936563-96-1 Puritas >99.5% (HPLC) API
Nomen chemicum | Ibrutinib |
Synonyma | 1-[(3R) -3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- unus;PCI-32765 |
CAS Number | 936563-96-1 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C25H24N6O2 |
M. Pondus | 440.50 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | White ad Off-Crystal pulveris |
Lepidium sativum | IR;HPLC |
Damnum in Siccatio | <0.50% |
Residere in Ignition | ≤0.10% |
Metalla gravia (ut Pb) | ≤20ppm |
Unam immunditiam | ≤0.20% |
Totalis immunditias | <0.50% |
Puritas / Analysis Methodus | >99.5% (HPLC) |
Test Standard | Enterprise Standard |
Consuetudinem | API |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
Ibrutinib (CAS: 936563-96-1) est inhibitor tyrosini kinasi Brutonis (BTK) ad curationem lymphocytici longi (CLL) et pallium cellae lymphomae (MCL).Tam MCL quam CLL pertinent ad lymphoma B-cell non Hodgkin, quod est refractarium et pronum ad relapsus.Communis usus chemoimmunotherapy non iaculis est, et gradus 3 vel 4 adversae motus saepe occurrunt.Ibrutinib coniungi potest cum BTK, quae necessaria est ad formationem, differentiam, communicationem et salutem lymphocytorum B, et irrevocabiliter actionem BTK inhibere, efficaciter inhibere proliferation et superstes cellularum tumoris.Praeterea, post administrationem oris celeriter absorbetur, maxima concentratio plasma 1~2h pervenit, et adversae reactiones sunt gradus 1 vel 2, quae nova optio fiet pro curatione CLL et MCL.Die XIII mensis Novembris anno MMXIII, US FDA accelerare probatus Johnson & Johnson societatem Imbruvicam et Civitates Americae Unitas (nomen commune Ibrutinib) ad tractandum lymphoma cellae manticae (MCL).Ibrutinib, concessum est status breakthrough Therapy a FDA in Februario 2013 et probatus est pro MCL die 13 Novembris, 2013 et CLL in die 12 Februarii 2014, respective.
-
Ibrutinib CAS 936563-96-1 Puritas >99.5% (HPLC) API
-
(S) -1-Boc-3-Hydroxypiperidine CAS 143900-44-1 I...
-
4-Phenoxyphenylboronic Acidum CAS 51067-38-0 Ibru...
-
Ibrutinib Deacryloylpiperidine CAS 330786-24-8.
-
Ibrutinib Intermedia CAS 330792-70-6 Munditia >...
-
4-Amino-3-Iodo-1H-Pyrazolo[3,4-d]pyrimidine CAS...
-
1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibruti...
-
3-Hydroxypiperidine CAS 6859-99-0 Ibrutinib Int...
-
4-Phenoxybenzoicum Acidum CAS 2215-77-2 Ibrutinib I...
-
4-Aminopyrazolo[3,4-d]pyrimidine CAS 2380-63-4 ...